OBESITY and DIABETES
Confronting a Global Obesity Epidemic with Cutting-Edge Solutions
Obesity has emerged as a worldwide epidemic, primarily driven by increased consumption of nutritionally poor foods laden with high-fructose sugars and harmful trans fats. Coupled with a widespread lack of exercise, these habits lead to excessive fat accumulation in tissues, contributing to severe health risks such as diabetes, cardiovascular disease, and other metabolic disorders. The United States and Mexico are particularly affected, ranking among the top ten countries globally in cases of obesity and diabetes.
Revolutionizing Diabetes Treatment with Natural, Next-Generation Products
In response to this urgent health crisis, Zephyr Labz is pioneering the development of a breakthrough, all-natural diabetes medication. Our research and product development teams focus on harnessing powerful, clinically-proven ingredients that offer a safer, more effective alternative to conventional treatments. By reducing reliance on single-target pharmaceuticals and adopting a holistic, multi-targeted approach, we aim to improve patient outcomes and address the root causes of obesity-driven diabetes.
Strengthening Market Position and Driving Valuation
As Zephyr Labz continues to innovate and expand our diabetes product line, we are poised to enhance our market presence and overall company valuation. Our dedication to pushing the boundaries of science—through advanced research, strategic partnerships, and cutting-edge formulations—ensures that we remain at the forefront of next-generation healthcare solutions. By providing safe, natural, and clinically effective treatments, Zephyr Labz is committed to empowering individuals worldwide in their journey toward healthier lives and sustainable weight management.

Mahmoud, AM. An overview of epigenetics in obesity: the role of lifestyle and therapeutic interventions. Int J Mol Sci. (2022) 23:1341. doi: 10.3390/ijms23031341
Flórez, KR, Dubowitz, T, Saito, N, Borges, G, and Breslau, J. Mexico–United States migration and the prevalence of obesity: a transnational perspective. Arch Intern Med. (2012) 172:1760. doi: 10.1001/2013.jamainternmed.770
RESEARCH FOCUS

The increasing public awareness of side effects associated with GLP-1 drugs like Ozempic and Semaglutide presents a significant opportunity for natural products that offer similar benefits without the drawbacks.1
Fueled by the surge in demand for Novo Nordisk’s GLP-1 medication Semaglutide and Eli Lilly’s GLP-1 and GIP drug Tirzepatide, investors are increasingly eager to bet big money on the next generation of weight loss drugs.2
Zephyr has prepared a multinational (US and Mexico) protocol for clinical study submission of our patented natural type II diabetes compound (that reduces blood glucose levels and insulin dependency).
The potential impact of Zephyr's planned bi-national clinical study could lead to a significant advancement in diabetes treatment. The development of a new, effective, natural diabetes medication could have a profound impact on patients worldwide.
Early clinical evidence shows significant improvements in key health markers, including blood glucose, hemoglobin A1c, cholesterol, and triglycerides. Beneficial effects on diabetic neuropathy have also been reported.
Zephyr's approach to drug development, which incorporates the development of new molecular entities as well as novel drug delivery technologies, will allow us to create truly transformative treatments with the potential to improve the lives of millions of people.
In addition to the development of the Company's natural diabetes and GLP-1 product line, current Company research on the side effects on overall health caused by current pharmaceutical GLP-1 products could further enhance Zephyr Group's market position and valuation.
Whether it’s slowing the effects of aging, improving skin elasticity, reducing inflammation and pain, or treating debilitating illness, Zephyr Group is positioning itself at the forefront of medical innovation.
Compounded Semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns1
Ozempic Could Be Blinding People Trying to Lose Weight2
The Opportunity of a Natural, Side-Effect-Free Alternative to GLP-1 Drugs
By addressing these challenges and capitalizing on the opportunities, a natural product line that effectively addresses the needs of consumers seeking safe and effective weight management solutions can carve a significant niche in the market.

GLP-1 Market
The global GLP-1 receptor agonist market size was estimated at USD 53.46 billion in 2024 and is projected to grow at a CAGR of 17.46% from 2025 to 2030. The launch of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a strong product pipeline for both diabetes & obesity applications, and the high efficacy of these drugs are anticipated to propel Zephyr in the market.
The surge in popularity of GLP-1 receptor agonists (GLP-1 RAs) presents a significant opportunity for various sectors.
- GLP-1 has long been a pharmaceutical target for obesity and diabetes. Most modern obesity drugs are based on the manipulation of GLP-1 and GIP. There is strong evidence that GLP-1 and the endocannabinoid CB1 receptor have strong interactions.
- Zephyr is utilizing advanced technologies like AI and machine learning to identify new drug targets and develop innovative GLP-1 RA therapies.